Best Small-Cap Medical Device Stocks for 2026: Your Investment Guide

MDxHealth (NASDAQ: MDXH) is a commercial-stage precision diagnostics company that's making significant strides in the detection of urologic cancers, particularly prostate cancer. They use advanced genomic, epigenetic, and exosomal technologies to offer non-invasive, tissue-based diagnostic assays. For retail investors, this means they're focused on a critical area of healthcare with a clear need for improved diagnostic tools. As of December 31, 2025, MDxHealth had a market capitalization of approximately $173.24 million, placing it firmly in the small-cap category.

A key development for MDxHealth was its acquisition of Exosome Diagnostics in September 2025 for $15 million. This strategic move added the ExoDx Prostate urine test to its portfolio, along with a CLIA-certified clinical laboratory. The company anticipates this acquisition will generate over $20 million in revenue in 2026, showcasing a clear path to increased commercial revenue. While specific Q1 2026 earnings data for MDxHealth was not immediately available, the company's focus on expanding its diagnostic offerings and its projected revenue growth from the Exosome Diagnostics acquisition highlight its potential in the diagnostics space. Investors will be watching for continued execution on these growth initiatives and further updates on their financial performance throughout the year.

KORU Medical Systems (NASDAQ: KRMD) is a medical device company specializing in mechanical infusion products, primarily for subcutaneous drug delivery. Their flagship product, the Freedom Syringe Infusion System, first received FDA clearance back in 1994, demonstrating a long-standing presence in the market. The company develops and manufactures these devices and supplies for both the U.S. and international markets, focusing on improving the patient experience for at-home infusions. As of December 31, 2025, KORU Medical Systems had a market cap of around $269.6 million.

A significant recent catalyst for KORU Medical Systems occurred on December 30, 2025, when the company submitted a 510(k) premarket notification to the FDA. This submission seeks clearance for its FreedomEdge system to deliver Phesgo, a HER2+ breast cancer targeted biologic, subcutaneously. This move is part of KORU's strategy to expand the indications of its FreedomEdge system into the broader oncology infusion center market, aiming to reduce chair time and improve efficiency for patients and healthcare providers. This potential FDA clearance represents a crucial step in expanding their addressable market and could significantly impact their revenue generation in 2026 and beyond. While specific Q1 2026 financial results were not readily available, this regulatory progress is a key indicator of the company's growth trajectory.

Vivani Medical (NASDAQ: VANI) is a clinical-stage biopharmaceutical company that’s taking an innovative approach to treating chronic conditions like obesity and type 2 diabetes. Instead of daily pills or weekly injections, Vivani is developing miniature, long-term subdermal drug implants using its proprietary NanoPortal technology. These implants are designed to provide a steady drug release over six months, potentially improving patient adherence and tolerability. As of December 31, 2025, Vivani Medical had a market capitalization of approximately $86.81 million.

In August 2025, Vivani Medical reported positive Phase 1 results from its LIBERATE-1 trial for the NPM-115 exenatide implant, confirming its safety and steady drug release for obesity treatment without major side effects. Building on this success, the company is rapidly advancing its NPM-139 semaglutide implant, which achieved sustained 20% weight loss in preclinical results. Vivani plans to initiate a Phase 1 clinical study for NPM-139 in the first half of 2026. While Vivani is still in the clinical stage, meaning its revenue is pre-commercial, these positive trial results and upcoming clinical milestones are significant catalysts that could drive future growth and investor interest. The company's focus on long-term implants addresses a clear market need for improved convenience and adherence in chronic disease management.

Orthofix Medical Inc. (NASDAQ: OFIX) is a global medical technology company focused on delivering orthopedic and spine solutions. Their operations are primarily divided into Global Spine and Global Limb Reconstruction segments, offering products like bone growth therapies and spinal implants. Orthofix had a market capitalization of approximately $401.39 million as of July 6, 2026.

Orthofix experienced a significant stock surge of 16% on July 6, 2026, following a crucial policy shift from the Centers for Medicare & Medicaid Services (CMS). CMS reversed its previous decision regarding the classification of non-invasive bone growth stimulators, a change that analysts suggest could restore reimbursement rates to prior levels. This is a vital development for the company's revenue generation, especially for its Global Spine segment, which includes bone growth therapies. While analysts are cautiously optimistic, acknowledging that future reimbursement evaluations remain uncertain, this reversal is a positive near-term catalyst. For the first quarter of 2026, Orthofix reported net sales of $196.7 million, surpassing analyst expectations, and reaffirmed its full-year 2026 financial guidance. However, the company did revise its full-year 2026 net sales projections to a range of $838 million to $848 million in May 2026, with non-GAAP adjusted EBITDA expected between $90 million and $93 million, partly due to earlier Medicare reimbursement changes before the recent reversal.

Accuray Incorporated (NASDAQ: ARAY) is a medical technology company that develops, sells, and supports radiation therapy systems used in cancer treatment and neuro-radiosurgery. Their key products include the CyberKnife and Radixact treatment platforms, which focus on precise, image-guided radiation delivery. Accuray aims to provide advanced oncology treatment solutions to healthcare providers globally. As of June 4, 2026, Accuray had a market capitalization of approximately $47.37 million, placing it in the micro-cap segment but still relevant for small-cap investors.

In May 2026, Accuray reported its fiscal third-quarter 2026 results (for the period ended March 31, 2026), with total net revenue of $104.8 million, a 7% decrease year-over-year. The company also reported a GAAP net loss of $11.8 million. Accuray withdrew its full-year fiscal 2026 revenue and Adjusted EBITDA guidance due to geopolitical uncertainty in the Middle East, which has impacted product shipments and service revenue. Despite these challenges, Accuray is actively implementing a transformation plan, launched in December 2025, focused on organizational realignment and cost-saving initiatives. This plan is already delivering cost and margin improvements, with approximately $10 million achieved through the fiscal third quarter, positioning the company to exceed its $12 million FY26 target. Additionally, in June 2026, Accuray fully repaid and retired $18 million in convertible senior notes due 2026, simplifying its capital structure. These operational improvements and debt reduction efforts could provide a foundation for future stability and growth once market conditions stabilize.